AUM Biosciences Enters into Collaboration with Roche for Clinical Development of AUM001 in Combination with anti-PD-L1 Therapy in Solid Tumor Indications
May 10, 2022 08:00 ET
|
AUM Biosciences
SINGAPORE and BETHESDA, MD, May 10, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company focused on discovering and developing novel targeted oncology therapies, today...
AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer
May 05, 2022 08:00 ET
|
AUM Biosciences
SINGAPORE, May 05, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing novel targeted oncology therapies, today announced that it...
AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2022
April 19, 2022 08:00 ET
|
AUM Biosciences
SINGAPORE and SEOUL, South Korea, April 19, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing novel targeted oncology...
AUM Biosciences와 HANDOK, ESMO Targeted Anticancer Therapies Congress 2022에서 AUM-601에 대한 임상1상 데이터 공개
April 19, 2022 08:00 ET
|
AUM Biosciences
싱가포르/한국 서울, April 19, 2022 (GLOBE NEWSWIRE) -- 임상 단계 바이오테크 기업으로 항암 신약 치료제 발견 및 개발에 중점을 두고 있는 AUM Biosciences는 한국의 혁신 주도 제약 및 헬스케어 회사인 Handok Inc. [002390: KOSPI], CMG Pharmaceutical Co. Ltd....